141 related articles for article (PubMed ID: 8217614)
61. High-dose melphalan and autologous bone marrow transplant for relapsed acute leukaemia.
Maraninchi D; Abecasis M; Gastaut JA; Sebahoun G; Cahn JY; Hervé P; Novakovitch G; Carcassonne Y
Cancer Chemother Pharmacol; 1983; 10(2):109-11. PubMed ID: 6339094
[TBL] [Abstract][Full Text] [Related]
62. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
Hájek R; Adam Z; Vásová I; Král Z
Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
[TBL] [Abstract][Full Text] [Related]
63. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
64. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
McElwain TJ; Powles RL
Lancet; 1983 Oct; 2(8354):822-4. PubMed ID: 6137651
[TBL] [Abstract][Full Text] [Related]
65. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
[TBL] [Abstract][Full Text] [Related]
66. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA
Med Oncol; 2002; 19(4):219-26. PubMed ID: 12512915
[TBL] [Abstract][Full Text] [Related]
67. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
68. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Sirohi B; Powles R; Treleaven J; Mainwaring P; Kulkarni S; Pandha H; Bhagwati N; Horton C; Singhal S; Mehta J
Bone Marrow Transplant; 2000 Mar; 25(5):533-9. PubMed ID: 10713631
[TBL] [Abstract][Full Text] [Related]
69. Triple MEL100 therapy in multiple myeloma.
Berz D; Colvin GA; McCormack EM; Winer ES; Karwan P; Colvin L; Rathore R; Lum LG; Elfenbein GJ; Quesenberry PJ
Transplant Proc; 2009 Nov; 41(9):3863-7. PubMed ID: 19917402
[TBL] [Abstract][Full Text] [Related]
70. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
71. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
[TBL] [Abstract][Full Text] [Related]
72. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
Singhal S; Powles R; Sirohi B; Treleaven J; Kulkarni S; Mehta J
Bone Marrow Transplant; 2002 Nov; 30(10):673-9. PubMed ID: 12420206
[TBL] [Abstract][Full Text] [Related]
73. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
Donato ML; Aleman A; Champlin RE; Weber D; Alexanian R; Ippoliti CM; de Lima M; Anagnostopoulos A; Giralt S
Leuk Lymphoma; 2004 Apr; 45(4):755-9. PubMed ID: 15160952
[TBL] [Abstract][Full Text] [Related]
74. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
75. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.
Barlogie B; Hall R; Zander A; Dicke K; Alexanian R
Blood; 1986 May; 67(5):1298-301. PubMed ID: 3516252
[TBL] [Abstract][Full Text] [Related]
76. The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma.
Schey SA; Kazmi M; Ireland R; Lakhani A
Eur J Haematol; 1998 Nov; 61(5):306-10. PubMed ID: 9855245
[TBL] [Abstract][Full Text] [Related]
77. Multiple myeloma--complete remission with high dose melphalan chemotherapy.
Richards F; Coleman M; Cooper MR; Ballard WP
Cancer Invest; 1985; 3(1):15-21. PubMed ID: 3971199
[TBL] [Abstract][Full Text] [Related]
78. Long-term low dose melphalan treatment of multiple myeloma.
Brook J; Bateman JR; Gocka EF; Nakamura E; Steinfeld JL
Arch Intern Med; 1973 Apr; 131(4):545-8. PubMed ID: 4699959
[No Abstract] [Full Text] [Related]
79. Melphalan and myeloma. Experience with a low-dose continuous regimen.
McArthur JR; Athens JW; Wintrobe MM; Cartwright GE
Ann Intern Med; 1970 May; 72(5):665-70. PubMed ID: 5448096
[No Abstract] [Full Text] [Related]
80. Oral dosage of melphalan and response to treatment in multiple myeloma.
Fernberg JO; Johansson B; Lewensohn R; Mellstedt H
Eur J Cancer; 1990 Mar; 26(3):393-6. PubMed ID: 2141499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
